RecruitingPhase 2NCT05677152

Influence of an Anti-osteoporotic Drug on Healing After Surgical Repair of Chronic Rotator Cuff Lesions of the Shoulder

Studying Chronic graft versus host disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AUVA Traumazentrum Vienna Site UKH Meidling
Principal Investigator
Jakob Schanda, DDr.
AUVA Traumazentrum Vienna Site UKH Meidling
Intervention
Intravenous Infusion of Aclasta®(drug)
Enrollment
80 target
Eligibility
50-70 years · All sexes
Timeline
2022 – 2030

Study locations (1)

Collaborators

Ludwig Boltzmann Institute for Traumatology - The research center in cooperation with AUVA

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05677152 on ClinicalTrials.gov

Other trials for Chronic graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Chronic graft versus host disease →

← Back to all trials